14 min
MIRA Pharmaceuticals, Inc. Erez Aminov, CEO The Wall Street Resource
-
- Investing
MIRA is developing a new
molecular synthetic THC analog called MIRA1a, designed for the treatment of
adult patients with anxiety and cognitive decline, typically associated with
early-stage dementia.
MIRA’s initial focus will
be a dual path: potentially winning in traditional pain and anxiety markets as
well as the marijuana analog markets with a potentially safe and effective option if approved
by the FDA.
MIRA is developing a new
molecular synthetic THC analog called MIRA1a, designed for the treatment of
adult patients with anxiety and cognitive decline, typically associated with
early-stage dementia.
MIRA’s initial focus will
be a dual path: potentially winning in traditional pain and anxiety markets as
well as the marijuana analog markets with a potentially safe and effective option if approved
by the FDA.
14 min